JAZZ · CIK 0001232524 · operating
Jazz Pharmaceuticals plc is a biopharmaceutical company that identifies, develops, and commercializes pharmaceutical products for neurological, oncological, and hematological conditions. The company's marketed portfolio includes Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for seizure disorders, and several oncology products including Rylaze, Zepzelca, Ziihera, and Modeyso targeting indications such as acute lymphoblastic leukemia, small cell lung cancer, and diffuse midline glioma. The company also markets Defitelio for severe veno-occlusive disease.
Jazz Pharmaceuticals operates a clinical pipeline spanning Phase 1 through Phase 3 development. Key programs in late-stage development include Zanidatamab for HER2-positive gastroesophageal and biliary tract cancers, Dordaviprone for H3 K27M-mutant diffuse glioma, and Vyxeos for myeloid malignancies. The company maintains licensing and collaboration agreements with multiple pharmaceutical and biotechnology partners including Redx Pharma, Zymeworks, and Sumitomo Pharma.
Based in Dublin, Ireland and listed on Nasdaq, Jazz Pharmaceuticals operates across the United States, Europe, and international markets with approximately 2,890 full-time employees. The company was incorporated in 2003.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-5.84 | $-5.84 | -167.5% | |
| 2024 | $8.65 | $9.06 | +41.8% | |
| 2023 | $6.10 | $6.55 | +270.4% | |
| 2022 | $-3.58 | $-3.58 | +35.1% | |
| 2021 | $-5.52 | $-5.52 | -336.9% | |
| 2020 | $2.33 | $2.39 | +80.6% | |
| 2019 | $1.29 | $1.31 | -51.1% | |
| 2018 | $2.64 | $2.69 | -30.3% | |
| 2017 | $3.79 | $3.87 | +98.4% | |
| 2016 | $1.91 | $1.95 | +44.7% | |
| 2015 | $1.32 | $1.35 | +1.5% | |
| 2014 | $1.30 | $1.35 | +44.4% | |
| 2013 | $0.90 | $0.96 | -81.2% | |
| 2012 | $4.79 | $5.09 | +506.3% | |
| 2011 | $0.79 | $0.88 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-24 | 0001232524-26-000013 | SEC ↗ |
| 2024-12-31 | 2025-02-26 | 0001232524-25-000011 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0001232524-24-000015 | SEC ↗ |
| 2022-12-31 | 2023-03-01 | 0001232524-23-000015 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001232524-22-000012 | SEC ↗ |
| 2020-12-31 | 2021-02-23 | 0001232524-21-000016 | SEC ↗ |
| 2019-12-31 | 2020-02-25 | 0001232524-20-000016 | SEC ↗ |
| 2018-12-31 | 2019-02-26 | 0001232524-19-000013 | SEC ↗ |
| 2017-12-31 | 2018-02-27 | 0001232524-18-000018 | SEC ↗ |
| 2016-12-31 | 2017-02-28 | 0001232524-17-000024 | SEC ↗ |